

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshiaki Sai, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126 (Public Relations)

+81-3-6225-1125 (Investor Relations)

<http://www.daiichisankyo.com/>

Notice of Commencing Open Offer for Shares in Zenotech Laboratories Limited

TOKYO, Japan (August 4, 2010) – Daiichi Sankyo Company, Limited (TSE: 4568; head office: Chuo-ku, Tokyo; hereafter, Daiichi Sankyo) had announced the postponement of its open offer for acquisition of the common stock of Zenotech Laboratories Limited (BSE:532039; head office in Hyderabad, India; hereafter, Zenotech) on August 10, 2009.

In this regard, Daiichi Sankyo announced today that it has commenced an open offer to the public shareholders of Zenotech (the “Offer”), in accordance with the Indian regulations. The details of the Offer are summarized below.

Outline of the Offer

(1) Period of the Offer

From August 4, 2010 through August 23, 2010 (Indian Standard Time)

(2) Type of Share Certificates, etc. subject to the Offer:

Common Stock

(3) Offer Price:

Rs113.62 per share

(4) Number of Share Certificates, etc. planned to be purchased:

Maximum 6,886,000 Shares

(5) Aggregate Price of the Offer:

Maximum of Rs782 million (JPY1,565 million, currency exchange rate: Rs1=JPY2.0)

(6) Others:

This Offer follows the judgment of Supreme Court of India in respect of the Offer Price and is being made in accordance with the Indian regulations.

<Disclaimer>

Statements contained in this press release regarding the benefits of the acquisition, the business outlook, the demand for the products and services, and all other statements in this release other than recitation of historical facts are forward-looking statements. Words such as “expect”, “estimate”, “project”, “budget”, “forecast”, “anticipate”, “intend”, “plan”, “may”, “will”, “could”, “should”, “believes”, “predicts”, “potential”, “continue”, and similar expressions are intended to identify such forward-looking statements.

Forward-looking statements in this press release include, without limitation, forecasts of market growth, future revenues, benefits of the proposed acquisition, expectations that the acquisition will be accretive to the results, future expectations concerning growth of business, cost competitiveness and expansion of global reach following the acquisition, and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: difficulties encountered in integrating businesses; uncertainties as to the timing of the acquisition; the satisfaction of the closing conditions to the transaction, including the receipt of regulatory approvals; whether certain market segments grow as anticipated; the competitive environment in the pharmaceutical industry and competitive responses to the proposed acquisition; and whether the companies can successfully develop new products and the degree to which these gain market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. This document does not constitute an offer to purchase or to sell securities in any jurisdiction.